ISSN: 2249-9504
CAS CODEN: IJPCDX

Abstracted and Indexed

open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing open access publisher, open access publishing, open access journals and articles, peer reviewed open access journals, insight medical publishing
+32 25889658
Google Scholar citation report
Citations : 3566

International Journal of Pharmaceutical, Chemical and Biological Sciences received 3566 citations as per google scholar report

International Journal of Pharmaceutical, Chemical and Biological Sciences peer review process verified at publons

A REGULATORY PERSPECTIVE OF 505(b) (2) NEW DRUG APPLICATION

Abstract

Author(s): P. Nagaraju, K. Gowthami*, T. Lakshmi, MV. Nagabhushanam, D. Nagarjuna Reddy

UShavebeenconsideredprimary pharmaceuticalmarketintheworldsince longback.USpharmaceuticalmarketshares30to35% ofglobalpharmaceutical marketdespitelowgrowthrate inlasttwoyears.TremendousgrowthofUSpharma sectorisbasedonthreeprevailingfactorslikepresenceofbigpharma playersinthe county,governmentwillingnesstoprovide healthcarefacility andthirdlargest populationwith315million.Pharmacompanieshave threeways,NDA (NewDrug Application),ANDA(AbbreviatedNew DrugApplication)andOTC(Over The Counter)monograph,tomarkettheirdrugproductsinUS.NDA505(b) (2)isoneof thetypesof NDA. Section505(b)(2)wasintroducedinFD&CactthroughHatchWaxmanAct1984andbecomingpopularday by dayduetoitsimportance.505(b)(2) applicationhaschangedtheconceptof new drugdefinition.505(b)(2) isstillunder its revolvingstageandFDAistakingallstepstokeepthings inlinewithout compromising to safety &efficacy which are utmost important from FDA perspective.FDAhasstartedemphasizingonaccess,affordabilityandqualityofdrug. ShortageofdrugisbeingaprobleminUSand 505(b)(2)applicationhascomein support ofFDA to solveit because it takes less timeto get through regulatory approvalprocess.505(b)(2)applicationmotivatesinnovationandatthesametime drugproduct pricedonotsurge highlike 505(b)(1)applicationduetoitslow requirementoffinanceindrugdevelopmentphase.Keepingaboveviewpointin mind,thisstudy encompassesdevelopmentof505(b)(2)applicationinthehistory of FDA,eligibility for505(b)(2)application,submissionrequirementsanddetailed CDER (Centerof DrugEvaluation and Research)reviewprocess ofNDA.

Get the App